Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepsin-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HPN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HPN ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HPN Products |
| Gene Delivery | HPN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HPN Products |
| Benchmark Ab | Anti-HPN Recombinant Reference Antibody Recombinant positive control for assay validation. |
View HPN Products |
| Validator | HPN siRNA Set For knockdown verification and specificity controls. |
View HPN Products |
| Related Target A | TMPRSS2 Homologous type II transmembrane serine protease; critical for off-target and selectivity screening. |
View TMPRSS2 Products |
| Related Target B | ST14 (Matriptase) Co-expressed serine protease in epithelial tumors; essential for counter-screening to ensure safety. |
View ST14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against homologous serine proteases | Homolog panel proteins (TMPRSS2, ST14) strictly verified by mass spectrometry and sequence analysis. |
| Conformational integrity of recombinant extracellular domain | HEK293 expressed recombinant HPN ECD with native glycosylation and sequence-verified active site. |
| Lack of positive control benchmarks | Clinical-grade benchmark antibodies included in the catalog for reliable assay setup. |
| Target validation false positives | Sequence-verified siRNA sets included for target knockdown and specificity validation. |
Live HPN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HPN (Hepsin) therapeutics is intensifying, with major players shifting focus from traditional small-molecule serine protease inhibitors to highly targeted monoclonal antibodies and Antibody-Drug Conjugates (ADCs). As first-generation diagnostic and therapeutic tools reach preclinical and early clinical validation, the next wave of R&D is targeting HPN-mediated cleavage pathways (such as pro-HGF activation) in advanced prostate and ovarian cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech Innovators | Prostate Cancer, Ovarian Cancer | Internalization Assay (Requires high-purity ECD-Fc for binding kinetics) |
| Small Molecule Inhibitor | Academic Institutes, Pharma | Metastatic Solid Tumors | Enzymatic Inhibition Assay (Requires active, native-conformation recombinant HPN) |
| Monoclonal Antibody (Blocking) | Oncology Therapeutics Developers | Prostate Carcinoma | Selectivity Screening (Requires homolog panel proteins like TMPRSS2, ST14) |